Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1. fázis

A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I

A legfontosabb adatok

Ki végzi
West China Hospital
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
6 fő, tervezett
Kezdés
2024. júl. 22.
Várható befejezés
2029. jún. 22.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • JWK008 Single intravenous infusion administration
A regiszteradat frissítve
2024. július 25.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • Age≥ 18 years old
  • Diagnosis of MPS type I
  • Be able to understand the purpose, content, and possible risks of this clinical study, voluntarily participate in and sign the informed consent form
  • If the subject is female, her sexual partner must agree to use reliable contraception until 2 consecutive tests of vector sequence in the blood are negative; If the subject is male, the subject agrees to use reliable contraception until the semen sample is negative for 2 consecutive tests of the vector sequence
  • Magnetic resonance imaging (MRI) of the liver mass read by the radiologist is negative

Ki nem vehet részt

  • Known to be unresponsive to ERT; or those who have been treated with intrathecal or intravenous laronidase and have serious adverse reactions, such as significant infusion-related reactions (IARs) or anaphylactic shock
  • Has contraindications for Corticosteroids
  • Current treatment with systemic (intravenous or oral) immunomodulators or steroid use (topical treatments such as asthma or eczema are allowed)
  • Previously received gene therapy or participated in interventional clinical studies within the past 12 weeks
  • The researcher believes that the subject is not suitable to participate in any concurrent clinically significant major diseases or other situations in the study
  • Have a history of chronic infections or other chronic diseases that researchers believe pose an unacceptable risk
  • Active severe infection or any other significant accompanying, uncontrolled medical condition(except for those caused by MPS I), including but not limited to kidney, liver, blood, gastrointestinal, endocrine, lung, nervous system, brain or mental illness, alcoholism, drug dependence, or any psychological disorder assessed by the researcher that may interfere with adherence to experimental protocol procedures or tolerance to JWK008 injection
  • History of active malignancy within the past 5 years (non-melanotic skin cancer or carcinoma in situ of the cervix is allowed)
  • Serum AAV5 neutralizing antibody titer is greater than 1:100
  • When filtering, one of the following situations exists:; Hepatitis B surface antigen (HBsAg) is positive, and the copy number of hepatitis B virus deoxyribonucleic acid (HBV-DNA) is>the upper limit of normal value (ULN); Hepatitis C virus antibody (HCV-Ab) is positive, and the copy number of hepatitis C virus ribonucleic acid (HCV-RNA) is>ULN; Receiving antiviral treatment for hepatitis B or C; The human immunodeficiency virus (HIV) test is positive and the CD4+T lymphocyte count is ≤ 200/mm3
  • Abnormal laboratory values considered clinically significant (ALT and/or AST >3× upper limit of normal (ULN), total bilirubin > 1.5× ULN, serum creatinine > 1.5× ULN, etc.)
  • Has contraindications for lumbar puncture
  • Circulating alpha-fetoprotein (AFP) is elevated or abnormal
  • Pregnant or lactating females
  • Unable or unwilling to comply with the visit and study evaluation schedule described in the clinical protocol

Ez a vizsgálat jelenleg itt érhető el: Kína.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a single-center, single-arm, non-randomized, open-label, non controlled, dose-escalation, prospective clinical trial designed to assess the safety, tolerability, and preliminary efficacy of JWK008 injection in patients with MPS I.

A vizsgálat csoportja

  • JWK008 injectionA vizsgált kezelés

    The participants will be given 5.0×10\^12vg/kg or 2.0×10\^13vg/kg body weight of JWK008

    Kezelés: JWK008 Single intravenous infusion administration

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 Given by a Single Intravenous Infusion in Patients With Mucopolysaccharidosis Type I
A regiszteradat frissítve
2024. július 25.